advertising
-
1
Schmoeckel C, Castro CE, Braun-Falco O: Nevoid malignant melanoma. Arch Dermatol Res 277: 362, 1985.
-
2
Knöpfel N, Martín-Santiago A, Del Pozo LJ, et al.: Amelanotic naevoid melanoma in a 16-month-old albino infant. Clin Exp Dermatol 42: 84, 2017.
-
3
Cassarino DS, Fullen DR, Sondak VK, et al.: Metastatic nevoid melanoma in a 4 1/2-year-old child. J Cutan Pathol 30: 647, 2003.
-
4
Zembowicz A, McCusker M, Chiarelli C, et al.: Morphological analysis of nevoid melanoma: a study of 20 cases with a review of the literature. Am J Dermatopathol 23: 167, 2001.
-
5
Pampena R, Lai M, Lombardi M, et al.: Clinical and dermoscopic features associated with difficult-to-recognize variants of cutaneous melanoma: a systematic review. JAMA Dermatol 156: 430, 2020.
-
6
Idriss MH, Rizwan L, Sferuzza A, et al.: Nevoid melanoma: a study of 43 cases with emphasis on growth pattern. J Am Acad Dermatol 73: 836, 2015.
-
7
Longo C, Piana S, Marghoob A, et al.: Morphological features of naevoid melanoma: results of a multicentre study of the International Dermoscopy Society. Br J Dermatol 172: 961, 2015.
-
8
Mesbah Ardakani N, Singh S, Thomas C, et al.: Mitotically active nevus and nevoid melanoma: a clinicopathological and molecular study. Am J Dermatopathol 43: 182, 2021.
-
9
Magro CM, Crowson AN, Mihm MC: Unusual variants of malignant melanoma. Mod Pathol 19(suppl 2): S41, 2006.
-
10
Yélamos O, Busam KJ, Lee C, et al.: Morphologic clues and utility of fluorescence in situ hybridization for the diagnosis of nevoid melanoma. J Cutan Pathol 42: 796, 2015.
-
11
Gerami P, Wass A, Mafee M, et al.: Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi. Am J Surg Pathol 33: 1783, 2009.
-
12
Jackett LA, Colebatch AJ, Rawson RV, et al.: Molecular profiling of noncoding mutations distinguishes nevoid melanomas from mitotically active nevi in pregnancy. Am J Surg Pathol 44: 357, 2020.
-
13
Gerami P, Li G, Pouryazdanparast P, et al.: A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol 36: 808, 2012.
-
14
Lezcano C, Jungbluth AA, Busam KJ: Comparison of immunohistochemistry for PRAME with cytogenetic test results in the evaluation of challenging melanocytic tumors. Am J Surg Pathol 44: 893, 2020.
-
15
Ihle MA, Fassunke J, König K, et al.: Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600e and non-p.V600e BRAF mutations. BMC Cancer 14: 13, 2014.
-
16
Richtig G, Hoeller C, Kashofer K, et al.: Beyond the BRAFV600e hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients. Br J Dermatol 177: 936, 2017.
-
17
Cheng L, Lopez-Beltran A, Massari F, et al.: Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol 31: 24, 2018.
-
18
Long GV, Menzies AM, Nagrial AM, et al.: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29: 1239, 2011.
-
19
Ribas A, Flaherty KT: BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 8: 426, 2011.
-
20
Hugdahl E, Kalvenes MB, Puntervoll HE, et al.: BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. Br J Cancer 114: 801, 2016.
-
21
Pratilas CA, Solit DB: Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 16: 3329, 2010.
-
22
Cohen C, Zavala-Pompa A, Sequeira JH, et al.: Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8: 3728, 2002.
-
23
Long GV, Weber JS, Infante JR, et al.: Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 34: 871, 2016.
-
24
Long GV, Stroyakovskiy D, Gogas H, et al.: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386: 444, 2015.
-
25
Robert C, Karaszewska B, Schachter J, et al.: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372: 30, 2015.
-
26
Ascierto PA, McArthur GA, Dréno B, et al.: Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17: 1248, 2016.
-
27
McArthur GA, Chapman PB, Robert C, et al.: Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15: 323, 2014.
-
28
Hao X, Yim J, Chang S, et al.: Acral lentiginous melanoma of foot and ankle: a clinicopathological study of 7 cases. Anticancer Res 39: 6175, 2019.
-
29
Ascierto PA, Del Vecchio M, Mandalá M, et al.: Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 21: 1465, 2020.
A Subungual Nevoid Melanoma of the Right Hallux from a 65-Year-Old Man: A Case Report
Search for other papers by Mark Quist in
Current site
Google Scholar
PubMed
Search for other papers by Joon Yim in
Current site
Google Scholar
PubMed
Search for other papers by Gene Mirkin in
Current site
Google Scholar
PubMed
Search for other papers by Xingpei Hao in
Current site
Google Scholar
PubMed
Nevoid melanoma (NeM) is a rare variant of malignant melanoma characterized by slight cellular atypia, polymorphism, and incomplete maturation. It most frequently occurs on the trunk and arms but rarely on the foot. Here, we report a subungual NeM of the right hallux. A 65-year-old man presented with severe pain of 6 months’ duration to his right great toe following self-treatment for an ingrown nail. He was evaluated and treated with debridement of the toenail at an urgent medical center 3 months prior. However, this had not relieved his pain. The patient also noticed discoloration of his distal great toe over the past 3 months. Removal of part of the ingrown nail revealed a pigmented mass extending distally from the matrix. Surgical excision of the mass was performed because of the concern for malignancy. The diagnosis of NeM was based on histologic analysis along with enhanced diagnostic modalities. The patient was further treated with surgical amputation of the great toe and anti–programmed cell death-1 therapy. The patient had no relapse at 1-year follow-up. Nevoid melanoma is a rare variant of malignant melanoma on the toes, which needs to be differentiated from a nevus with atypia, with a variety of modalities including cellular and molecular profiling. The optimal treatment is amputation.
advertising
